866-997-4948(US-Canada Toll Free)

Novolog (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 44 Pages


GlobalData has released its new report, Novolog (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Novolog is a fast-acting insulin analog, developed by Novo Nordisk and launched in 2000. It is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker\'s yeast) as the production organism. This analog has increased charge repulsion, which prevents the formation of hexamers, leading to a faster-acting insulin.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Novolog including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Novolog for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Novolog performance
  • Obtain sales forecast for Novolog from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Novolog/NovoRapid (insulin aspart) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 29
6.4 SWOT Analysis 29
6.5 Forecast 30

7 Appendix 31
7.1 Bibliography 31
7.2 Abbreviations 34
7.3 Methodology 35
7.4 Forecasting Methodology 35
7.4.1 Diagnosed Type 2 Patients 35
7.4.2 Percent Drug-Treated Patients 36
7.4.3 Drugs Included in Each Therapeutic Class 36
7.4.4 Launch and Patent Expiry Dates 37
7.4.5 General Pricing Assumptions 37
7.4.6 Individual Drug Assumptions 38
7.4.7 Generic Erosion 38
7.5 Physicians and Specialists Included in this Study 39
7.6 About the Authors 41
7.6.1 Analyst II - CVMD 41
7.6.2 Therapy Director - CVMD and Infectious Disease 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Novolog 28
Table 7: Novolog SWOT Analysis, 2012 29
Table 8: Global Sales Forecasts ($m) for Novolog, 2012-2022 30
Table 9: Key Launch Dates 37
Table 10: Key Patent Expiries 37
Table 11: Number of High-Prescribing Physicians Surveyed 40

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *